Published in final edited form as:

Cell Mol Life Sci. 2010 February ; 67(4): 581–600. doi:10.1007/s00018-009-0182-4.

Cerebral amyloidosis: amyloid subunits, mutants and phenotypes

A. Rostagno,

Department of Pathology, New York University School of Medicine, New York, NY 10016, USA,
agueda.rostagno@nyumc.org

J. L. Holton,

Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square Brain Bank
for Neurological Disorders, University College London, Queen Square, London WC1N 3BG, UK,
j.holton@ion.ucl.ac.uk

T. Lashley,

Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square Brain Bank
for Neurological Disorders, University College London, Queen Square, London WC1N 3BG, UK,
t.lashley@ion.ucl.ac.uk

T. Revesz, and

Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square Brain Bank
for Neurological Disorders, University College London, Queen Square, London WC1N 3BG, UK,
t.revesz@ion.ucl.ac.uk

J. Ghiso

Department of Pathology, New York University School of Medicine, New York, NY 10016, USA,
Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA,
jorge.ghiso@nyumc.org

Abstract

Cerebral amyloid diseases are part of a complex group of chronic and progressive entities bracketed together under the common denomination of protein folding disorders and characterized by the intra- and extracellular accumulation of fibrillar aggregates. Of the more than 25 unrelated proteins known to produce amyloidosis in humans only about a third of them are associated with cerebral deposits translating in cognitive deficits, dementia, stroke, cerebellar and extrapyramidal signs, or a combination thereof. The familial forms reviewed herein, although infrequent, provide unique paradigms to examine the role of amyloid in the mechanism of disease pathogenesis and to dissect the link between vascular and parenchymal amyloid deposition and their differential contribution to neurodegeneration.

Keywords

Amyloid proteins; Cerebral amyloid angiopathy; Amyloid plaques; Protein folding disorders

Introduction

Cerebral amyloid diseases are considered to be part of an emerging complex group of chronic and progressive entities collectively known as “Disorders of Protein Folding” that

include, among many others, Alzheimer's disease (AD), polyglutamine-repeat disorders, cataracts, amyotrophic lateral sclerosis, Parkinson's disease and other synucleinopathies, tauopathies, a variety of systemic amyloidosis, prion diseases, cerebellar ataxias and type-II diabetes [1–4]. In all these diseases, through mechanistic pathways poorly understood, soluble proteins normally found in biological fluids change their conformation and form either insoluble aggregates that accumulate intra- or extra-cellularly or fibrillar lesions usually associated with local release of inflammatory mediators, oxidative stress, complement activation, cell toxicity, apoptosis, or a combination thereof resulting in cell damage, organ dysfunction and eventually death.

Regardless of the organ targeted and the misfolded protein involved, all extracellular fibrillar deposits, generically referred to as amyloid, share common physical, structural, and tinctorial properties. In general, they are: (1) highly polymerized and poorly soluble assemblies, features that preclude their efficient physiologic *in vivo* removal by macrophages requiring the use of strong detergents, harsh acid conditions or concentrated chaotropes to partially extract them *in vitro* from the tissue deposits; (2) weakly antigenic, consistently failing to induce a high titer response or high affinity antibodies in different animal species; (3) structurally rich in β -pleated sheet conformations, a property accountable for the apple-green birefringence of the deposits when observed under polarized light after Congo red staining as well as for their yellow–green fluorescence after thioflavin S staining; and (4) fibrillar in shape when negatively stained and observed under the electron microscope [5–7].

Amyloid proteins

Amyloid fibrils are composed of self-assembled, low-molecular-weight peptides usually representing fragments of larger precursor molecules normally present in body fluids. In humans, more than 25 different proteins are known to self-assemble and form fibrillar amyloid structures. The respective precursors are totally unrelated proteins which under physiologic conditions exhibit a wide range of biological functions (Table 1). Despite these differences, all share the conformational, immunogenic, and tinctorial properties described above and are typically constituted of molecules in the mass range of 4–30 kDa with frequent heterogeneity at the amino and/or carboxyl-terminal ends.

Cerebral amyloid diseases

The most frequent forms of amyloidoses are those localized to the central nervous system (CNS). Only about one-third of amyloid proteins known to be linked to disease in humans (Table 1) produce fibrillar deposits in the CNS which, in turn, translate in cognitive deficits, dementia, stroke, cerebellar and extrapyramidal signs, or a combination thereof. Classical lesions in the CNS, illustrated in Fig. 1, are usually found in the form of: (1) parenchymal preamyloid deposits, amorphous non-fibrillar structures negative under Congo red or thioflavin S staining, which are visualized by their diffuse immunoreactivity with specific antibodies, and are extractable by treatment with aqueous buffers in the presence of mild detergents; (2) parenchymal fibrillar amyloid lesions, usually in the form of compact plaques exhibiting extensive Congo red/thioflavin S staining, which are immunoreactive with specific antibodies and poorly soluble, requiring the use of either chaotropes (e.g., 6 M guanidine-HCl) or strong acids (e.g., formic acid) to be retrieved from the lesions; and (3) cerebral amyloid angiopathy (CAA), Congo red/thioflavin S positive fibrillar deposits affecting the media and adventitia of medium-sized and small cerebral arteries and arterioles as well as many cerebral capillaries. In general terms, stroke—either ischemic or hemorrhagic—is the most common clinical manifestation of amyloid deposition primarily

restricted to cerebral vessel walls, whereas widespread distribution throughout brain parenchymal areas is concomitantly associated with dementia.

A β -related cerebral amyloidoses

Sporadic AD

Late-onset (sporadic) AD is the most common form of dementia in humans over the age of 65 and affects more than 50% of individuals 85 or older. It is a debilitating neurodegenerative disorder that directly affects millions of people and indirectly touches the lives of tens of millions of others who must deal with many years of cognitive decline of their loved ones. Currently, with an estimated 5.3 million Americans having AD and a health care cost of more than US\$148 billion each year, the disease is one of the major public health concerns, not only in the US but in all developed countries. These figures are likely to increase dramatically in the next decades with the aging of the world population. Advances in medicine and medical technology, as well as improved social and environmental conditions, are expanding life expectancy with significant numbers living well into their 80s and 90s. Since the incidence and prevalence of AD and other dementias increase with age, the number of people with these conditions will also grow rapidly unless new therapeutic avenues are discovered precluding or at least delaying the disease onset.

Neuropathological hallmarks of AD (Fig. 1a–c), described more than 100 years ago, are the presence of intraneuronal neurofibrillary tangles (NFT)—deposits of hyperphosphorylated protein tau in the form of paired helical filaments—together with the existence of parenchymal extracellular deposits composed of both diffuse preamyloid lesions and mature amyloid plaques. Together with these features, fibrillar amyloid deposition is also commonly observed in medium-sized and small cerebral vessels. Although its significance was ignored for decades, the vascular dysfunction resulting from amyloid deposition at the cerebral vessel walls is considered today an active player in the mechanism of neurodegeneration and a major contributor to the disease pathogenesis [8–12]. Cerebrovascular and parenchymal lesions are composed of self-aggregates of A β protein generated by proteolytic cleavage of a larger precursor APP by the so-called β and γ secretases [7, 13, 14]. While a single protein, BACE1, is responsible for the β -secretase activity, γ -secretase is composed of four essential subunits: presenilin-1 (PS1) or presenilin-2 (PS2), together with nicastrin, APH-1, and PEN-2 [15, 16]. The γ -secretase complex cleaves at multiple sites within the transmembrane domain of APP, generating A β peptides ranging in length from 38 to 42 residues [17]. Nearly 90% of secreted A β ends at residue 40, whereas A β 42 accounts for only <10%, and peptides ending at residues 38 are minor components [15]. Notably, the pattern and distribution of these species varies among the different topographical lesions. Parenchymal deposits consist of A β 42 as the major component, whereas vascular A β —particularly in the large leptomeningeal vessels—is primarily composed of A β 40 species organized in large concentric sheets and replacing the smooth muscle cell layer [18]. Amyloid associated with arterioles and small cortical arteries contains a mixture of A β 40 and A β 42, while deposits affecting the capillary network are mainly composed of A β 42 [19]. The reasons for this selectivity as well as its importance for the pathogenesis of the disease remain unclear.

Familial AD

Early-onset familial forms of AD with clinical symptoms appearing before the age of 65 account for less than 5–10% of the total cases. They are linked to mutations in three different genes codifying for APP, PS1, and PS2. In addition, specific allelic combinations of the *APOE* gene have been linked to AD as a risk factor for the disease [20]. The *APOE* ϵ 4 genotype which occurs in 16% of the population [21] is the major susceptibility gene

identified in the human genome for both rare early-onset and sporadic late-onset AD [22]. Nevertheless, in spite of this association, many $\epsilon 4$ -positive individuals do not develop AD and many AD patients do not carry these genes suggesting that APOE $\epsilon 4$ gene may act as a molecular chaperone promoting fibrillogenesis and deposition of A β [23].

Of the genes directly related to the development of familial AD, *PSEN1* and *PSEN2* mutations affect the levels of A β 42 production, whereas nucleotide changes within the APP molecule have a differential effect depending on the location of the mutated residue (Fig. 2). Amino acid substitutions flanking the A β region in close proximity to the β -secretase cleavage site modulate the rate of enzymatic processing of APP, resulting in increased production of A β 42 and A β 40 while maintaining the ratio A β 42/A β 40 unaffected and translating in a classic early-onset AD clinical phenotype [24,25]. As illustrated in Fig. 2, the Swedish double mutation (K670N/M671L) [26] increases the production of A β 40 and A β 42 by >5-fold, a feature that has been reproduced with transfected cells in culture [27,28]. Similarly, the recently reported Italian mutation (A673V) [29] that manifests as early-onset AD only in homozygous individuals (see below) shows enhanced production of both A β species by ~2-fold maintaining the ratio A β 42/A β 40 unaltered, features also reproduced in cell cultures. In contrast, the numerous mutations occurring in close proximity to the γ -secretase cleavage sites are typically associated with increased production of A β 42—and, in many instances, lower levels of A β 40—in a similar manner to the effect caused by mutations in the presenilin genes [27,30]. As a result, the ratio A β 42/A β 40 in all these mutants is several fold elevated, in some cases reaching ~18-fold values (see Fig. 2). Amino acid substitutions within residues 21–23 and 34 of the A β peptide are, with few exceptions [31], associated with prominent vascular compromise. As detailed below, many of these mutants are primarily associated with episodes of cerebral hemorrhage rather than dementia. For space considerations, we will limit this review to those A β variants located within the A β sequence. A complete list of all reported APP genetic variants as well as the pertinent references may be found at the Alzheimer Disease and Frontotemporal Dementia Mutation Database (<http://www.molgen.ua.ac.be/ADMutations/>) and have been reviewed in [25].

A β mutations within the 21–23 amino acid residue cluster

The A β region comprising residues 21–23 is considered a “hot spot” for mutations due to the high number of genetic variants reported in this area of the molecule. Mutations within this amino acid cluster, described below, typically show strong vascular compromise and primarily associate with CAA, hemorrhagic strokes and dementia.

A β E22Q mutation—The first described intra-A β mutation was found in a condition known as hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-Dutch), an autosomal dominant disorder clinically defined by recurrent strokes, vascular dementia, and fatal cerebral bleeding in the fifth to sixth decades of life. The mutation in which Gln replaces a Glu residue at position 22 (A β E22Q) results from a single nucleotide transversion (G for C) at codon 693 [32]. Carriers of the mutation develop recurrent episodes of cerebral hemorrhages correlating with massive amyloid deposition in the walls of leptomeningeal and cortical arteries and arterioles (Fig. 1d), as well as in vessels in the brainstem and cerebellum [33], a phenotype recapitulated, albeit at old age, in transgenic mice carrying the mutation [34]. In addition to the vascular involvement, parenchymal amyloid deposits resembling the diffuse preamyloid lesions seen in AD are also observed in Dutch familial cases, while dense-core plaques and neurofibrillary tangles are rare or even completely absent [32]. The non-fibrillar diffuse plaques, variably associated with reactive astrocytes and activated microglia [35], seem to evolve into more fibrillar, dense lesions which are more abundant in older patients while younger patients have more fine diffuse plaques [36]. Nevertheless, the degree of dementia appears to be independent of plaque involvement and

neurofibrillary degeneration, which is absent or limited, and contrastingly correlates with the severity of CAA [37].

A β 1-40 is the predominant A β species of HCHWA-D vascular amyloid, with wild-type and Dutch-type mutated sequences present at a 1:1 molar ratio. In contrast, A β 1-42 is only a minor component of the vascular deposits [34,38,39] and is uniquely associated with species bearing the mutation and not with those originated from the normal allele [40]. In cerebral cortex A β 1-42 forms—either wild-type or carrying the E22Q substitution—were not detectable by western blotting, and the A β 1-42:A β 1-40 ratio, as determined by ELISA, was considerably lower than in AD cases [34].

In vitro cell culture studies demonstrate that E22Q has potent toxic effects on cerebrovascular endothelial and smooth muscle cells [41,42], likely reflecting the in vivo hemorrhage-associated phenotype. The variant is a strong inducer of the Bax pro-apoptotic mitochondrial pathway leading to the release of cytochrome *c* to the cytosol, events accompanied by downstream nuclear fragmentation [43]. The effect of E22Q on endothelial cells goes beyond the induction of apoptosis. The variant is also a potent angiogenesis inhibitor, affecting the FGF-2 signaling pathway, downregulating phosphorylation of the FGF-2 receptor, and the Akt survival signaling [44]. All these events lead to the ultimate endothelial dysfunction and are likely to contribute—solely or partially—to the disturbances in membrane permeability and hemorrhagic manifestations present in the kindred.

E22 Δ deletion mutation—Recently, a novel deletion mutation of the APP gene (E693 Δ) was reported in Japan in patients showing Alzheimer's-type dementia and which results in a variant-A β lacking Glu at position 22 [45]. No neuropathological information is available to date on these cases but in vitro culture experiments indicate enhanced intracellular accumulation and markedly reduced secretion of this variant-A β in transfected cells. Notably, intracellular E22 Δ was found to be predominantly composed of oligomeric forms which accumulate in endoplasmic reticulum, Golgi apparatus, early and late endosomes, lysosomes, and autophagosomes [40], all of which have been proposed as intracellular sites of A β generation and/or degradation, suggesting an impairment of APP/A β trafficking associated with the mutation. Consistent with the nonfibrillogenic property of E22 Δ , a very low amyloid signal was observed in the patient's brain on positron emission tomography using Pittsburgh compound-B, pointing out to synaptotoxic A β oligomers as the likely cause of dementia in this pedigree [45,46].

Aggregation studies using synthetic homologues demonstrated that A β E22 Δ is more resistant than wild-type A β to proteolytic degradation exhibiting a unique property of enhanced oligomerization in the absence of fibrillization. In line with the notion of oligomeric assemblies as the culprit of AD pathogenesis, E22 Δ inhibits hippocampal long-term potentiation more powerfully than wild-type A β upon injection into rat cerebral ventricles.

A β E22K mutation—The substitution of G for A at codon 693 resulting in a Glu for Lys amino acid change at position 22, the same site of the Dutch mutation, was found in three apparently unrelated Italian families [41]. This genetic variant, although much less studied than the Dutch, is also linked to familial CAA with cerebral hemorrhage. The disease, associated with early onset and death between ages of 65 and 75, is clinically characterized by a 10- to 20-year progression of recurrent strokes and mild cognitive decline. The neuropathological findings also appear to resemble those in the Dutch kindred with extensive A β deposits in the walls of leptomeningeal and cortical vessels. The parenchymal compromise is limited to diffuse thioflavin S-negative deposits with absence of mature plaques and neurofibrillary tangles. Immunochemical studies with C-terminal specific

antibodies indicate that, as it is most common in CAA pathology including that associated with the Dutch variant [36], A β 40 species predominate in the vascular deposits and A β 42 in the parenchyma.

The Italian variant exhibits in vitro a predominantly unordered secondary structure and a low fibrillization tendency resulting in the formation of atypical fibrils—short and straight, without the distinctive twisted pattern characteristic of most amyloid molecules and at an even lower rate than the A β 40 wild-type counterpart [41]. These conformational properties correlate well with the predominantly thioflavin S-negative fluorescence of the parenchymal and vascular deposits observed in the Italian kindred, as well as with the lack of toxicity for vessel wall cells exhibited by synthetic homologues of the genetic variant. The lower capacity of Italian-A β to induce apoptosis in cerebrovascular endothelial cells in comparison to the Dutch variant may in turn reflect the later onset of the disease.

A β E22G mutation—A form of AD affecting a family of northern Sweden and spanning four generations is characterized by a different genetic substitution, A to G also at codon 693, known as the Arctic mutation, and which results in the substitution of Glu for Gly at position 22 of A β . The phenotypic manifestation of the disease is memory impairment at early onset—mean age 57 years—with progressive cognitive decline rather than stroke [47]. The clinical history is typical of AD but without the severe amyloid angiopathy that characterizes the other mutations within the A β sequence. The disease shows a slow insidious progression and decline in short-term memory as the first presenting symptoms with no signs of strokes or significant vascular involvement found in the cases that were subjected to neuroimaging studies. The parenchymal compromise is recapitulated in transgenic mice carrying the Arctic mutation which show an aggressive formation of plaque deposits in association with dystrophic neurites and in the absence of vascular involvement. However, the disease appears to be pleiotropic since one possibly related Swedish patient with the same mutation demonstrated moderate to severe CAA in cortical and leptomeningeal vessels as well as senile plaques and neurofibrillary tangles [48].

In vitro, E22G induces a dramatic increase in the rate and capacity to form protofibrils in comparison to the wild-type counterpart [47], significantly enhancing the peptide insolubility, a phenomenon likely correlating with the accelerated disease initiation and progression observed in vivo. E22G had a weaker apoptotic effect on cerebrovascular endothelial cells in comparison with the hemorrhage-associated E22Q correlating with the absence of stroke and hemorrhagic manifestations in the Arctic kindred [44]. Notably, carriers of the Arctic mutation show lower levels of both A β 42 and A β 40 than healthy family members, a feature observed even in very young mutation carriers—20–30 years before the expected onset of the disease—suggesting a long period of biochemical abnormality before the clinical onset. The decreased levels of A β peptides observed in the Arctic cases were also reproduced in transfected cell lines and have been claimed to reflect an altered APP processing induced by the mutation [47].

A β A21G mutation—The Flemish mutation is a C to G transversion at codon 692 of APP resulting in an Ala for Gly substitution at position 21 of A β and leading to a form of AD with prominent amyloid angiopathy. The presence of the mutation which correlates with early onset of the disease and death occurring at a mean age of 53, has been reported in two kindreds, a four-generation Dutch family with 17 affected members [49] and a British family with five affected individuals. Whereas some of the cases presented with lobar intracerebral hemorrhage, other members in both pedigrees developed presenile dementia. Neuropathologically, affected brains demonstrate diffuse cortical atrophy and an abundance of vascular and parenchymal A β deposits, primarily ending at position 40, together with neurofibrillary tangles. Vascular amyloid, present in cortical and leptomeningeal vessel

walls, accumulate in the basement membrane of small vessels and capillaries. Although diffuse plaques are present, there is a predominance of mature plaques, typically surrounded by tau-reactive dystrophic neurites and which exhibit atypically large cores that may account up to 48% of the entire plaque size. Remarkably, these plaques are mostly of perivascular or vasocentric nature appearing to radiate from the affected vessel, a feature which suggests that the AD pathology might be a secondary consequence to CAA.

In contrasting difference to other mutations occurring within the A β sequence, the Flemish variant peptides display increased in vitro solubility and a decreased rate of protofibrillar structures formation in comparison with the wild-type counterparts [50]. Although Flemish homologues exhibit a time-dependent increase in thioflavin-T binding correlating with the formation of β -sheet-containing assemblies, there is an overall poor fibrillization tendency [51]. Moreover, once formed, fibrils exhibit morphological differences with the wild-type structures. Electron microscopic studies revealed variations in the diameter of the filaments, and in the extent and density of the lateral filament associations as well as in the helicity of the fibrils compared to wild-type fibrils. These structural differences have been claimed to potentially alter the thermodynamic stability of the fibrils and their ability to be metabolized or degraded, features that could explain the aggressiveness of the disease in spite of the higher solubility of the synthetic homologues [52].

A β D23N mutation—The Iowa genetic variant consists of a G to A substitution at codon 694 of APP, resulting in the change of Asp for Asn at residue 23 of A β , and a loss of a negatively charged residue, as in the Dutch substitution, occurring at the immediate location of the molecule. The genetic variant was identified in an Iowa family of German descent [53,54]. Patients of the Iowa kindred develop progressive, early onset AD-like memory impairment and personality changes with cerebral atrophy, leukoencephalopathy, and occipital lesions neuropathologically identified as calcified, amyloid-laden meningeal vessels. Although small hemorrhages could be identified by MRI and postmortem examination, there were no reported episodes of clinically manifest intracerebral hemorrhage. Of note, a second family from Spain, carrying an identical mutation, presents cerebral hemorrhage in the majority of the cases, suggesting that the mutation may or may not produce major hemorrhagic episodes under different biological conditions [55,56]. The neuropathological features of the Iowa variant consist of a predominant vascular compromise coexisting with scattered preamyloid deposits, abundant neurofibrillary tangles and dystrophic neurites in the presence of remarkably few mature plaques [53]. A wide range of CAA-associated changes have been described in Iowa patients including luminal narrowing, wall thickening, and occluded small vessels, together with loss of smooth muscle cells, microbleeds, and presence of perivascular inflammatory cells [57].

An interesting feature of the Iowa amyloid deposits is the presence of post-translationally modified iso-Asp residues, not only at the position of the mutation, residue 23, but also in the Asp residues at positions 1 and 7 [58]. The deposits, both vascular and parenchymal, exhibit a predominant A β 1-40 composition by immunohistochemistry while ELISA quantitation in brain homogenates revealed a 20-fold higher ratio of A β 1-40 over A β 1-42 [58]. Biochemical studies indicate that the brain deposits are highly heterogeneous at both N-, and C-termini and contained both mutated and non-mutated A β molecules [59], as also shown in Dutch deposits [39] and prion diseases [60], as well as in systemic forms of amyloidosis [61–65]. It is likely that the deposition of the respective mutated species exerts a seeding effect—or a conformational mimicry—enhancing the fibrillization and subsequent co-deposition of the wild-type counterparts, as previously proposed [66–68]. Synthetic homologues bearing the Iowa mutation, in a similar manner to the Dutch variant and in contrast to the Flemish, rapidly assemble in solution to form fibrils consistent with their high content in β -sheet secondary structure [51]. This conformational tendency for fibrillization

appears to confer, in turn, enhanced toxicity for smooth muscle cells in vitro with a concomitant decrease in the cells α -actin expression [41,69].

Intra-A β mutations located outside the cluster 21–23

A β amino acid substitutions outside positions 21–23, translate into clinical phenotypes of early-onset cognitive impairment associated or not with stroke and hemorrhage, depending on the specific location of the genetic variation. In some recently reported variants, the genetic defects were discovered by DNA sequencing on patients still alive, and therefore neuropathological information is unavailable at the moment.

A β L34V mutation—One of the most recently identified mutations that predominantly associates with CAA and recurrent cerebral hemorrhages is located within the A β sequence, but apart from the 21–23 cluster. The C to G transversion at codon 705 leads to a replacement of Leu at position 34 by a Val residue [70]. The mutation occurs in a three-generation family from the Piedmont region in Italy and presents with early onset, usually ranging between 50 and 72 years of age. The clinical features of the disease include recurrent hemorrhagic strokes, weakness and parasthesias together with confusional states. Cognitive impairment is infrequent as a presenting symptom but is observed after various episodes of intracerebral hemorrhages.

Neuropathological examination of the few available cases showed severe CAA with compromise of small and medium-size arteries as well as capillaries in all lobes of the brain, particularly the occipital and cerebellar regions. The vascular involvement includes vessel-within-the-vessel configurations, microhemorrhages, microaneurisms, microthrombi, and lymphocytic infiltration of the vessel walls. Diffuse and dense-cored plaques as well as neurofibrillary pathology were notably absent [54].

The limited studies currently available indicate that freshly solubilized L34V—similarly to wild-type A β —exhibits a predominantly unordered conformation but in difference to the non-mutated peptide its structure shifts to a mostly β -sheet profile by 24 h. This pro-amyloidogenic conformational change as well as the aggregation properties of the L34V resemble that of E22Q, although with more extended lag-phase and lower intensity, correlating with the comparable but less aggressive clinical phenotype of the Piedmont kindred [71]. In agreement with these structural data and the similar clinical manifestations, both variants elicit analogous caspase-mediated mitochondrial pathways in cerebral vessel wall cells, although within different time-frames and intensity [72]. These activated pathways are susceptible to pharmacologic modulation either through direct inhibition of mitochondrial cytochrome *c* release or by the action of pan and pathway-specific caspase inhibitors, giving clear indication of the independent or synergistic engagement of both extrinsic and intrinsic apoptotic mechanisms.

A β A42T mutation—A mutation at codon 713 of APP (G to A transition) resulting in an Ala for Thr substitution at position 42 of the A β molecule was reported in an Italian family of 54 members spanning four generations [73]. Notably, this mutation had been previously described in a single individual from France [74] but no clear-cut relationship with the disease pathogenesis could be demonstrated at that time. The mutation, of unknown penetrance since most healthy carriers are currently below the age of onset, is unique in view of the fact that, although located within the A β sequence, it is also adjacent to the γ -secretase cleavage site. The affected kindred presents an autosomal dominant form of dementia with clinical symptoms of AD, severe CAA, and multiple infarcts. Clinical manifestations include early age of onset—between 52 and 68 years—progressive cognitive decline, and stroke-like episodes including monoparesis and language disturbances. The

same A42T mutation was found in a family in Spain [75], which presented with comparable clinical manifestations as in the Italian cases. Neuropathologic examination in both kindreds revealed the presence of the hallmark lesions of AD, senile plaques, CAA, neurofibrillary tangles and neuropil threads. CAA was particularly severe with the presence of 8- to 10-nm fibrils within and around the vessel walls. Leptomeningeal arteries and small parenchymal vessels in the cerebral hemisphere and cerebellum were severely affected by amyloid deposition. The normal architecture of the compromised vessels was disrupted by amyloid deposition presenting thickening and double barreling of the walls, loss of smooth muscle cells, and narrowing of the lumina.

A β D7N mutation—A missense mutation of G for A in the first nucleotide of codon 678, which translates in an Asp for Asn substitution at position 7 of A β , was found in a Japanese-Tottori pedigree. The clinical manifestations of the mutation were symptoms of progressive dementia that fulfilled the NIN-CDS–ADRD criteria for AD [76]. Symptoms appeared at about 60 years of age, slowly worsening for more than a decade without signs of vascular involvement either clinically or neuroradiologically [31]. Both of the siblings studied were heterozygous for the mutation.

In vitro analyses demonstrated that the A β D7N substitution selectively accelerated the elongation phase of A β fibril formation. Unexpectedly, the process occurred without significant protofibril formation [77], thus different from wild-type A β 40 and A β 42 as well as other intra-A β mutations in which protofibril formation precedes the assembly of mature fibrillar conformations [47,50].

A β H6R mutation—A genetic variation at codon 678, adjacent to the location of the Tottori mutation, causing an amino acid substitution of His at position 6 with Arg was reported in a family from the United Kingdom [78]. Neuropathological studies confirmed the signature lesions of AD with an age of onset at 55 years. In spite of these findings, the pathogenicity of the mutation still requires further assessment since the genetic variation was present in only one of two siblings affected by AD [78]. The A β H6R mutation—like the Tottori—does not affect A β production. Synthetic homologues of both genetic variants, as indicated above, show enhanced fibrillogenesis selectively promoting the elongation phase of fibril formation. Notably, in both cases, the levels of protofibrils are markedly inhibited suggesting that the two mutations might induce unique mechanisms causing structural A β changes without increasing the formation of metastable intermediates [77].

A β E11K mutation—A mutation at codon 682 of APP was found in a family in Leuven, Belgium, which translates in a substitution of Glu for Lys at residue 11 of A β , a highly conserved position of the molecule [79]. The clinical manifestation of the mutation is an AD-like phenotype but with a very early age of onset (47 years). No neuropathological data is available to the moment for these cases.

Notably, the amino acid substitution is located at one of the two adjacent β -sites for APP cleavage by BACE 1. Although the β -secretase predominant cleavage point is found upstream in the APP molecule and results in the generation of A β 1-40/42 species, under certain conditions including specific sequence and structural constraints, the β -site originating A β 11-40/42 fragments also becomes significant. Studies examining the selectivity of the β -secretase cleavage of APP showed that blocking the β' -site by introducing the A β E11K variant in conjunction with the artificial A β Y10K mutation shifted BACE1 cleavage entirely to the β -site [80]. Whether any alterations in APP processing exist in patients bearing the A β E11K variant remains to be determined.

A β A2V mutation—The last intra-A β mutation reported to the moment consists of a C to T transition at position 673 that results in an Ala to Val substitution at residue 2 of A β and leads to AD only in the homozygous state. The genetic defect induces a very aggressive early-onset phenotype with established behavioral changes and cognitive deficits at the age of 36 which evolved toward severe dementia with spastic tetraparesis, and complete loss of autonomy in about 8 years. Notably, the disease affected two homozygous siblings while six relatives—aged between 21 and 88 years—who carried the mutation in the heterozygous state were not affected, as deduced by their neuropsychological assessment [29]. The A2V substitution appears to affect APP processing resulting in enhanced A β production with no alteration in the ratio of A β 42 to A β 40, similar to the K670N/M691L Swedish double mutation (Fig. 2).

In vitro studies of A β A2V fibrillogenesis showed that, as it happens with many other genetic variants, the presence of the mutation enhances the aggregation and fibrillogenic properties of the A β molecule [41,47,51]. Notably, the coexistence of the mutant peptide with equimolar concentrations of wild-type A β results in a clear inhibition of fibrillogenesis. It has been proposed that the interaction between both A β species interferes with the nucleation-dependent polymerization processes hindering amyloidogenesis and neurotoxicity. This negative effect on in vitro amyloid fibril formation induced by the coexistence of both subunits may correlate with the protective effect observed in the heterozygous carriers.

Non-A β Familial AD mutations

AD clinical phenotypes are also observed in patients with mutations in non-APP genes. Depending on the respective genes involved, some of these familial cases exhibit deposition of A β peptides (e.g., *PSEN* mutations) while others show deposition of unrelated amyloid molecules with clinical phenotypes of dementia and/or hemorrhagic stroke.

Presenilin mutations—PS mutations are associated, as described above, with the presence of familial forms of AD, accounting for ~80% of the early-onset AD cases. Although more than 120 mutations in the *PSEN1* gene have been associated with autosomal dominant early-onset AD, only eight missense mutations have been found in the *PSEN2* gene [81–87]. The phenotype associated with each genetic variant depends on the gene, type of mutation, and transmembrane domain affected [88]. Most of PS mutations are characterized by accelerated A β production, an onset before the age of 60 years, and an almost complete penetrance [82]. Only a few *PSEN2* mutations exhibit incomplete penetrance and variable clinical expression, overlapping with late-onset AD [89,90].

Of the many *PSEN1* and *PSEN2* mutations described, only a few are associated with the presence of CAA. Specifically, mutations located after codon 200 appear to result in a particularly severe vascular compromise. In cases with $\Delta 9$ and $\Delta I83/\Delta M84$ (Fig. 1e) deletions in the *PSEN1* gene, the clinical phenotype includes spastic paraparesis and cotton wool plaques together with extensive and severe CAA [91]. The predominance of cotton wool plaques is, however, not unique to these mutations as they have also been described in association with a number of other *PSEN1* genetic variants. CAA was also identified as a prominent feature in a Volga-German family characterized by the change of Asn for Ile at position 141 in the *PSEN2* gene. The mutation was also associated with cerebral hemorrhage in at least one case in the family. For a complete detailed list of PS1 and PS2 mutants see <http://www.molgen.ua.ac.be/ADMutations/>.

Non-A β cerebral amyloidosis

Cystatin C-related cerebral amyloidosis—Hereditary cerebral hemorrhage with amyloidosis, Icelandic type (HCHWA-Icelandic), is an autosomal dominant disorder described in individuals from small rural communities of western Iceland [92]. The disease is associated with a T to A point mutation [93], translating into a Leu for Gln change at position 68 of cystatin C, a ubiquitously expressed inhibitor of cysteine proteases codified by a single gene on chromosome 20. The 110-residue-long amyloid subunit constituting the amyloid deposits in HCHWA-Icelandic not only bears the mutated amino acid residue but it is also degraded at the N-terminus, starting at position 11 of the normal cystatin C [94,95]. The main clinical hallmark of the disease is cerebral hemorrhage with fatal outcome in the third to fourth decade of life in approximately 50% of the cases. Strokes are rare after the age of 50, and cognitive decline followed by dementia may occur in those cases that survive the hemorrhagic episodes. Neuropathologically, the mutation is associated with massive amyloid deposition within small arteries and arterioles of leptomeninges, cerebral cortex, basal ganglia, brainstem, and cerebellum (Fig. 1f). Although brain involvement is the main clinicopathological feature, silent amyloid deposits have also been described in peripheral tissues, such as skin, lymph nodes, spleen, salivary glands, and seminal vesicles.

The biochemical and structural properties of the variant form of cystatin C have been extensively studied. The mutated residue is located within the hydrophobic core of the protein and the amino acid substitution affects the stability of the molecule destabilizing alpha-helical structures and yielding a more unfolded molecule with higher tendency to form dimeric assemblies compared with the wild-type counterpart (reviewed in [96]). The crystal structure of the cystatin C variant revealed that dimerization occurs through three-dimensional domain swapping [97] and, in turn, through dimer association, results in the formation of larger amyloid-like structures with involvement of intermolecular β -sheet interactions [98]. The N-terminal truncation of the molecule found in vivo in the amyloid deposits of the Icelandic patients seems not to be crucial for the overall domain-swapped dimer formation; however, the absence of the N-terminal decapeptide appears to facilitate the subsequent association of the protein via β -sheet interactions through intermolecular contacts [99].

Gelsolin-related cerebral amyloidosis—Gelsolin-related amyloidosis, also known as familial amyloidosis Finnish type (FAF), is an autosomal dominant condition of systemic compromise characterized by ophthalmologic, dermatologic, and neurological symptoms with common cerebral amyloid deposition (reviewed in [100]). Although the majority of FAF patients have been reported in Finland with a marked geographic clustering of cases in the southeastern part of the country, the disease has worldwide distribution [101]. Two different mutations at codon 187 of gelsolin, an actin-binding protein, cosegregate with the disease. The first mutation, described in Finnish, Dutch, American, and Japanese families, results from a single G to A transition at position 654, the first nucleotide of codon 187 and translates in an Asp for Asn change [102–105]. A different amino acid substitution at the same nucleotide is present in patients of Danish and Czech origin suffering from the same disorder [101]. In these cases, a transition of G to T results in the presence of a Tyr instead of the normally occurring Asp.

Clinical manifestations result from the compromise of multiple organs and include peripheral neuropathy, facial palsy, dry and itchy skin, intermittent proteinuria, and cardiac symptoms. Patients have typical faces with droopy eyelids and protruding lips. Lattice corneal dystrophy, a lace-like deposition of amyloid within the stroma, is the earliest clinical finding of the syndrome. Amyloid deposition in the spinal and cerebral blood vessel walls, meninges, spinal nerve roots and sensory ganglia are critical features of this systemic

amyloidosis contributing to the CNS symptoms. Amyloid deposition in basement membranes and vessels (Fig. 1g) is common to most of the organs, in addition to the CNS [101].

Biochemical analysis of the deposits revealed that the amyloid fibrils are formed by a 7-kDa internal degradation product of the gelsolin molecule. This amyloid subunit is located in a repetitive motif with actin-binding activity—highly conserved among species—and spanning from position 173 to residue 243 of the gelsolin molecule [105].

Transthyretin-related cerebral amyloidosis—Familial transthyretin (TTR)-related amyloidosis is a systemic disorder usually associated with peripheral neuropathy and involvement of visceral organs, with only exceptional cases presenting with CNS compromise. Three unrelated families have been reported carrying different point mutations in the chromosome 18-*TTR* gene and showing abundant cerebral amyloid deposition in the presence of rare hemorrhagic episodes. The Hungarian kindred, consisting of 56 members spanning four generations, is associated with a single A for G missense mutation at codon 18 resulting in the presence of Gly instead of Asp [106,107]. The onset of symptoms varies between 36 and 53 years, with death occurring between the ages of 50 and 60. The major clinical symptoms include short-term memory decline, hearing loss, cerebellar dysfunction with ataxia, and bilateral pyramidal dysfunction with progressive spasticity. Most patients show temporary disorientation, and migraine-like headache with vomiting, and tremor. Neuropathological studies revealed extensive amyloid deposition (Fig. 1h) in meningeal vessels as well as in subarachnoid, subpial, and subependymal cerebrospinal regions, and spinal ganglia. Although not associated to any clinical symptoms, small systemic deposits were also present in kidney, skin, ovaries, and peripheral nerves.

A different mutation, T for G at codon 30 resulting in the substitution of Val for Gly and also presenting with CNS compromise, was identified in a large Ohio family of German ancestry consisting of 59 members spanning four generations [108]. The main clinical symptoms are slowly progressive dementia, seizures, ataxia, hemiparesis, decreased vision, and mutism. The age of onset is between 46 and 56 years with the duration of disease varying between 3 and 26 years. The histopathological hallmark is the presence of amyloid deposits in the subependymal region, the leptomeninges, the choroid plexus, and in the wall of the subarachnoid blood vessels. Small and medium-sized vessels are the most severely affected by amyloid even though notably, the vascular compromise is absent once the vessels penetrate into the brain parenchyma. Although not a frequent finding, vascular amyloid has also been described affecting vessels of virtually all visceral organs, skin, and skeletal muscle [109].

More recently, a different mutation in the *TTR* gene was linked to lethal CAA and cerebral hemorrhage in a single case in Japan [110]. The point mutation associated with the disease takes place also at codon 30 and results in the substitution of Val for Met. This mutation is the most common genetic variation related to the *TTR*-associated form of systemic amyloidosis known as familial amyloidotic polyneuropathy (FAP) which typically presents with massive amyloid deposition in the peripheral nervous and vascular systems as well as in systemic organs, but with uncommon cerebral compromise. The case, belonging to a typical FAP pedigree, presented with renal dysfunction as the starting symptom followed by cardiac involvement and death by complications of the heart condition. Histopathologic studies at autopsy disclosed, in addition to the systemic compromise, massive intracerebral hemorrhages in the absence of neurofibrillary tangles and senile plaques.

Cerebral amyloid formation was apparent not only in the choroid plexus and leptomeninges but also in dilated small arteries in the cerebral cortex. The case presents a striking

difference with typical FAP phenotypes associated with the identical mutation, in which amyloid accumulation in cerebrocortical vessels is not only significantly lower than the systemic deposition, but it has never been associated with hemorrhagic complications.

Immunoglobulin-related cerebral amyloidosis—Cerebral immunoglobulin-light-chain deposition is found in different clinicopathologic entities including amyloidoma, leptomeningeal vascular amyloidosis, solitary intracerebral plasmacytoma, primary intracerebral lymphoma with plasmacytic differentiation, and multiple sclerosis with demyelination-associated amyloid deposition, as well as in a proposed new entity named Widespread Subcortical Vascular Amyloidosis with Leukoencephalopathy (WSVAL) [111]. Of all these rare diseases with brain-restricted AL-type deposition, the most frequent form is the presence of amyloidomas which typically occur in the absence of systemic amyloidosis. Since the first description of tumor-like amyloid formations within the brain [112], only 27 cases have been described so far [113]. In addition to these, a few case reports describe amyloidomas localized in the head and nervous system including at the skull base [114], within the trigeminal nerve [115] and involving spinal and peripheral nerves [116–118].

Amyloidomas may occur in all brain regions with predominance of frontal lobe localization and close contact with the ventricle system. In most of the patients, the lesions were found within the white matter; only one case presented the tumor-like mass in the cortical tissue, while around 30% of cases showed simultaneous cortical and subcortical compromise [113].

The cases studied at immunohistochemical or biochemical levels demonstrated a high prominence of λ -chain with only two cases showing simultaneous λ and κ deposition without a predominance of one of the subtypes [111,113]. Recent studies using the state-of-the-art technology liquid chromatography-electrospray tandem mass spectrometry (LC/MS–MS) after laser-capture microdissection identified only λ -light chain as the component of the relative small number of amyloidomas studied [119].

Prion-related cerebral amyloidosis—A unique category in amyloid disorders is constituted by prion-related diseases, in which the etiology is thought to be related to the conversion, by a post-translational process, of the normal prion protein PrP^C into an infectious and pathogenic form PrP^{SC}. The infectious etiological agent is devoid of nucleic acids and was called prion to denote its proteinaceous nature and distinguish it from viruses and viroids [120]. The infective protein PrP^{SC} differs from the normal counterpart only in the conformational folding, in which the higher β -sheet content of the disease-associated form translates in enhanced propensity to aggregation and resistance to proteolysis. This group of diseases includes, among others, Creutzfeldt–Jakob disease (CJD), kuru, Gerstmann–Sträussler–Scheinker disease (GSS), and fatal familial insomnia in humans as well as scrapie and bovine spongiform encephalopathy in animals.

Extensive cortical spongiform change, gliosis, and neuronal loss are common but not invariable features of these disorders. Amyloid angiopathy is infrequent although it is noticeably present in rare hereditary disease forms, which are characterized by a premature stop codon mutation of the *PRPN* gene. Detailed neuropathological data have been documented in a single pedigree caused by a T to G mutation occurring at codon 145 and resulting in an early stop codon (Y145STOP) and the production of a N- and C-terminally truncated PrP peptide 70 amino acids long. In this genetic variant, the main neuropathological finding is PrP-immunoreactive-CAA in leptomeningeal and parenchymal blood vessels together with prominent perivascular amyloid deposition and neurofibrillary tangle pathology [121]. A similar mutation, Y163STOP, in a different family also presents with a neuropathological phenotype characterized by vascular and parenchymal disease-associated PrP deposition and extensive NFT pathology [25]. Both the Y145STOP and

Y163STOP mutations result in truncated C-termini with loss of the glycosylphosphatidylinositol (GPI) anchor, which is added post-translationally to the C-terminus of PrP and is required to attach it to the outer leaflet of the plasma membrane [122].

BRI2 gene-related dementias—This novel group of hereditary disorders, also known as chromosome 13 dementias, and composed of familial British and Danish dementias (FBD and FDD, respectively), presents with cognitive impairment as one of the main defining clinical phenotypes [123,124]. Both diseases, share many features with AD including the presence of neurofibrillary tangles, parenchymal preamyloid and amyloid deposits, extensive CAA and a variety of co-localized amyloid-associated proteins and inflammatory components. These early-onset conditions, as described below, are linked to specific mutations at or near the stop codon of the chromosome 13 gene *BRI2* that cause generation of longer-than-normal protein products.

Interesting new findings have demonstrated a cross-talk between BRI2 and APP that could bring new lights into the molecular mechanisms underlying neurodegeneration. Although BRI2 has still an unknown function, it was recently shown to specifically interact with APP. As a result of this binding interaction, BRI2 masks the cleavage sites of β - and α -secretase on APP and the γ -secretase docking site on the APP C-terminal fragment C99. As a consequence, BRI2 modulates APP processing inhibiting $A\beta$ formation and deposition properties, a feature observed in both cell culture and mouse models of AD [125–128].

Familial British dementia—This hereditary disorder originally reported in 1933, is the first described cerebral amyloidosis in the Western world [129] and affects an extensive pedigree of British origin which spans over nine generations [123]. The disease presents with early onset, typically around the fifth decade of life, being its earliest manifestations personality changes—with patients becoming irritable or depressed— followed by cerebellar ataxia and spastic paralysis more severe than that seen in atypical forms of AD or in GSS. Pseudo-bulbar palsy and dysarthria are universal and all patients progress to a chronic vegetative state becoming mute, unresponsive, quadriplegic, and incontinent. Neuropathologically, FBD cases exhibit severe and widespread amyloid angiopathy of the brain (Fig. 1i) and spinal cord and characteristic perivascular changes that include vessel-associated amyloid plaques and white matter changes resembling Binswanger's leukoencephalopathy. Notably, despite the extensive amyloid deposition in the vasculature, large intracerebral hemorrhage is a rare feature. Neuritic and non-neuritic amyloid plaques affect cerebellum, hippocampus, amygdala and, occasionally, cerebral cortex. Neurofibrillary degeneration is indistinguishable from that observed in AD cases. As it occurs in other forms of non- $A\beta$ cerebral amyloidosis described above, FBD presents systemic thioflavin-S-positive deposits in many organs, including pancreas, adrenal gland, lung, myocardium, liver, spleen, and skeletal muscle [130]. Nevertheless, this systemic deposition appears to be asymptomatic since clinical phenotypes of all described cases are only related to the cerebral compromise.

The disease is associated with a T to A substitution at codon 267 of *BRI2* which results in the presence of an Arg residue in place of the stop codon normally occurring in the wild-type precursor molecule and a longer open-reading frame of 277 amino acids instead of 266 [131]. Furin-like processing of this longer precursor releases a C-terminal fragment 34 amino acids long, named ABri, which is found constituting the characteristic cerebral and systemic deposits in FBD [130,131].

ABri synthetic homologues recapitulate in vitro the aggregation/fibrillization propensity observed in vivo in the tissue deposits by forming spontaneous β -sheet-rich structures and

exhibiting fast aggregation kinetics. In fact, ABri molecules demonstrate an even higher tendency to form high-ordered oligomeric assemblies than Alzheimer's A β 42. Consistent with the behavior of other amyloid forming proteins, ABri aggregation kinetics is favored by slightly acidic conditions which result in the formation of protofibrils as intermediate structures during fibril maturation [123].

Familial Danish dementia—Familial Danish dementia (FDD), also known as hereditary ophthalmic-oto-encephalica, is an early onset autosomal dominant disorder originating in the Djursland peninsula in Denmark and also associated with a genetic mutation in the *BRI2* gene [132]. A 10-nt duplication insertion mutation between codons 265 and 266 abolishes the normal stop codon and results, as in the case of FBD, in an extended precursor protein which possess 277 amino acids instead of the normal 266 [132,133]. The C-terminal peptide ADan (which is 34 amino acid long), as the ABri counterpart, is cleaved from the mutated precursor protein, and readily forms the deposited amyloid fibrils. The disease, identified in a single family and spanning three generations, is clinically characterized by the development of cataracts, hearing loss and progressive cerebellar ataxia before the age of 40 with subsequent paranoid psychosis and dementia. Death occurs in most patients during their fifth or sixth decade. The disease is characterized by diffuse brain atrophy with a severe involvement of the cerebellum, cerebral cortex, and white matter. Neuropathological characteristics, similarly to those seen in FBD, include widespread amyloid angiopathy (Fig. 1j) in the blood vessels of the cerebrum, choroid plexus, cerebellum, spinal cord, and retina. Neurofibrillary pathology is severe in the limbic structures and is also present in neocortical areas where it is more pronounced than in FBD. Abnormal neurites, as seen in some other forms of CAA, mainly cluster around the vascular deposits and are absent around nonfibrillar diffuse parenchymal lesions [134].

An interesting feature observed in FDD cases is the deposition of variable amounts of A β in blood vessels and, to a lesser extent, in brain parenchyma in the form of preamyloid deposits, either in combination with ADan or in isolated lesions [135]. Biochemical analysis of extracted brain amyloid revealed that CAA deposited A β is an N-terminal truncated form of A β 42, a surprising finding in view of the prevalence of A β ending at position 40 in vascular deposits observed in sporadic and familial AD, Down syndrome, and normal aging [66]. Detailed mass spectrometry analysis of extracted brain amyloids revealed that the deposited ADan species, similarly to the ABri counterparts, are post-translationally modified at the N-terminus [66,130]. The glutamate to pyroglutamate modification, involving the loss of one molecule of water, is notably not present in the circulating ADan or ABri counterparts, indicative of in situ generation. Similar modifications have been described in A β deposits [136,137] and appear to convey in vitro high insolubility and aggregation proclivity to the peptides, with significant changes in the oligomerization kinetics and enhanced toxicity [138]. It has been proposed that the presence of pGlu, even in minor concentrations, may act as potential seeding species for aggregate formation in vivo and even contribute to the formation of mixed aggregates such as those observed in FDD and composed of ADan and A β subunits [139].

Intracellular amyloid Tau

The original definition of amyloid [140] comprised only the extracellular deposition of fibrillar material exhibiting the typical tinctorial properties described above (e.g., birefringence after Congo red staining). It is now agreed that the definition needed to be expanded to incorporate intracellular aggregates sharing the classical amyloid properties. Although many different intranuclear or in-tracytoplasmatic protein inclusions have been described associated with specific diseases, the only intracellular components fulfilling the complete definition criteria of amyloid are the neurofibrillary tangles, exhibiting cross- β X-

ray diffraction pattern and typical Congo red and thioflavin-S staining [141]. Other intraneuronal inclusion bodies, such as Lewy bodies in Parkinson's disease, intranuclear inclusions in Huntington disease, as well as inclusions of neuroserpins and ferritin in familial neurodegenerative disorders, are not considered amyloids [142].

The presence of NFTs, one of the histopathological trademarks of AD, was described by Alois Alzheimer himself in affected limbic and cerebral cortices via light microscopic evaluation following silver tissue impregnation by the Bielschowsky method. Tangles are composed by building blocks of aberrantly phosphorylated species of the microtubule associated protein tau which accumulate in the perinuclear cytoplasm of selected neurons in the form of paired, helically wound filaments (PHF). These filaments aggregate into masses inside nerve cell bodies, known as NFT, in neuronal processes as neuropil threads, and as dystrophic neurites typically associated with the amyloid plaques [143,144], described above.

In addition to AD, NFT are also found in other neurodegenerative disorders grouped under the denomination of tauopathies. Some examples of tauopathies, in addition to AD, are certain forms of frontotemporal lobar degeneration including Pick's disease, progressive supranuclear palsy, and corticobasal degeneration [145]. The demonstration that mutations in the tau gene are associated with fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) has provided convincing evidence that tau protein plays a key role in neurodegeneration. This also suggests that distinct sets of tau isoforms expressed in different neuronal populations could lead to different pathologies [146].

Nature of the pathogenic subunits

Aggregation/fibrillization of amyloid subunits seems to play a critical role in neurodegeneration. It is now considered that the transition from soluble monomeric species circulating under normal conditions to the oligomeric, protofibrillar and end-point fibrillar assemblies contributes significantly to disease pathogenesis. In particular, intermediate oligomeric and protofibrillar forms of A β seem to display the most potent effects in neuronal cells inducing synaptic disruption and neurotoxicity [147,148], while in contrast, the abundance of mature amyloid plaques correlates poorly with AD severity [149,150]. Oligomeric intermediate assemblies also exhibit potent apoptotic properties for cerebral microvascular endothelial cells, an effect exacerbated in genetic variants associated with CAA and intracerebral hemorrhage like A β E22Q [43,44]. Although soluble A β oligomers have been observed in AD brains [151,152], there is no consensus regarding the exact nature of these pathogenic assemblies, their order of appearance in the aggregation process or whether they are transient intermediate species evolving into higher order conformers. A large and confusing body of literature exists describing many types of A β assembly forms, including protofibrils, annular structures, paranuclei, A β -derived diffusible ligands (ADDLs), globulomers and amyloid fibrils [147,153]. The basis for these discrepancies are the diverse experimental protocols comprising not only high variability among the source of A β synthetic homologues but also different solubilizing strategies combined or not with the use of alternative protocols to remove pre-existing β -sheet elements with potential seeding capability. An element contributing to these disparities is the broad definition of oligomers which, in general, are considered A β assemblies not-pelleted from the respective physiological or experimental fluids by high-speed centrifugation. As a result of this empiric definition, the structural assemblies encompassed in each category depend highly on the experimental conditions of each study.

Soluble prefibrillar oligomers have been implicated as primary causative agents not only in AD but also in many different degenerative diseases in which the additional accumulation of

large fibrillar deposits is seen by some as either of an inert or a protective nature [153]. Parkinson-related α -synuclein—like $A\beta$ —can form pore-like annular structures in vitro [154]. Mutations associated with early onset of the disease not only exhibit accelerated protofibrillar formation in vitro but in the case of A30P α -synuclein the presence of the mutation additionally slows the conversion of the protofibrillar intermediates into the insoluble amyloid fibrils [155–157]. Similar oligomeric assemblies have also been reported for components of the Huntington disease-related polyglutamine peptides [158] as well as for the amyloid subunits of the chromosome 13-associated dementias. In the latter case, the respective amyloid sub-units have been shown to undergo supramolecular conformational changes in reconstituted membranes forming morphologically compatible ion-channel-like structures and eliciting single ion-channel currents [133,159].

Conclusions and perspective

A clear understanding of the basic biochemistry of the key players in the molecular mechanisms of cerebral amyloidoses may ultimately provide a framework for developing drugs or other treatments to alleviate the severe pathology these molecules can cause in the elderly. Whether these treatments will eventually come as enzyme inhibitors, peptide aggregation blockers, trafficking modulators, immunization therapies, or a combination thereof, is not settled at this time. Science is still at a stage of development of the knowledge on the molecular basis of neurodegeneration. In spite of the many studies, significant breakthroughs in early diagnosis and therapeutics are pending, and relevant questions remain unanswered. Whether soluble oligomers bind to specific receptors, causing selective malfunctions in particular subsets of neurons, or whether the physical assembly of amyloidogenic proteins onto cellular membranes with ion-like channel formation cause the observed range of adverse signaling effects remain to be further elucidated. Also unknown is whether the amyloid assemblies formed under different conditions—exhibiting different sizes and structural conformations—or those originating from different amyloid subunits display unique toxic activities. The availability of familial forms of cerebral amyloidoses, either related to genetic variants of $A\beta$ or to non- $A\beta$ proteins, provides unique paradigms to examine the role of amyloid in the mechanism of disease pathogenesis and to dissect the link between vascular and parenchymal amyloid deposition and their differential contribution to neurodegeneration. At the moment, it seems clear that different amyloid species have the capability to induce similar neuropathological changes leading to the same scenario: neuronal loss and dementia. Unrelated peptides likely adopt similar altered amyloidogenic configurations and trigger comparable downstream detrimental effects in neuronal cells.

Acknowledgments

This work was partially funded by NIH grants NS051715, AG10491, and AG30539, the Alzheimer's Association, and the American Heart Association. The Queen Square Brain Bank is supported by the Reta Lila Weston Institute and by grants from the Progressive Supranuclear Palsy (Europe) Association. T.R. and J.L.H. are supported by the Sarah Matheson Trust for MSA and the Alzheimer's Research Trust. This study was also supported by the NIHR UCLH/UCL Comprehensive Biomedical Research Centre.

References

1. Dobson CM. Protein folding and its links with human disease. *Biochem Soc Symp.* 2001; 68:1–26. [PubMed: 11573341]
2. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. *Science.* 2002; 296:1991–1995. [PubMed: 12065827]
3. Lovestone S, McLoughlin DM. Protein aggregates and dementia: is there a common toxicity? *J Neurol Neurosurg Psychiatry.* 2002; 2002:152–161. [PubMed: 11796764]

4. Temussi PA, Masino L, Pastore A. From Alzheimer to Huntington: why is a structural understanding so difficult? *EMBO J.* 2003; 22:355–361. [PubMed: 12554637]
5. LeVine H. Thioflavine T interaction with amyloid β -sheet structures. *Amyloid.* 1995; 2:1–6.
6. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid by Congo red spectral shift assay. *Methods Enzymol.* 1999; 309:285–305. [PubMed: 10507031]
7. Ghiso J, Frangione B. Amyloidosis and Alzheimer's disease. *Adv Drug Delivery Rev.* 2002; 54:1539–1551.
8. Farkas E, Luiten PGM. Cerebral microvascular pathology in aging and Alzheimer's disease. *Prog Neurobiol.* 2001; 64:575–611. [PubMed: 11311463]
9. Bailey TL, Rivara CB, Rocher AB, Hof PR. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. *Neurol Res.* 2004; 26:573–578. [PubMed: 15265277]
10. de la Torre JC. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. *Neurol Res.* 2004; 26:517–524. [PubMed: 15265269]
11. Gorelick PB. Risk factors for vascular dementia and Alzheimer's disease. *Stroke.* 2004; 35:2620–2627. [PubMed: 15375299]
12. Petty MA, Wettstein JG. Elements of cerebral microvascular ischaemia. *Brain Res Rev.* 2001; 36:23–34. [PubMed: 11516770]
13. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA.* 1985; 82:4245–4249. [PubMed: 3159021]
14. Kang I, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature.* 1987; 325:733–736. [PubMed: 2881207]
15. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. *J Biol Chem.* 2008; 283:29615–29619. [PubMed: 18650430]
16. Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. *Curr Opin Neurobiol.* 2004; 14:379–383. [PubMed: 15194119]
17. Selkoe DJ, Wolfe MS. Presenilin: running with scissors in the membrane. *Cell.* 2007; 131:215–221. [PubMed: 17956719]
18. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ. Beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. *Proc Natl Acad Sci USA.* 1993; 90:10836–10840. [PubMed: 8248178]
19. Kokjohn TA, Roher A. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. *Alzheimers Dement.* 2009; 5:340–347. [PubMed: 19560104]
20. Roses A. Genetic testing for Alzheimer disease. Practical and ethical issues. *Arch Neurol.* 1997; 54:1226–1229. [PubMed: 9341568]
21. Roses A. A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease. *Neurogenetics.* 1997; 1:3–11. [PubMed: 10735268]
22. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. *J Clin Psychiatry.* 2007; 68:613–618. [PubMed: 17474819]
23. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. *Neurosci Lett.* 1992; 135:235–238. [PubMed: 1625800]
24. Selkoe D. Translating cell biology into therapeutic advances in Alzheimer's disease. *Nature.* 1999; 399:23–31.
25. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostagno A, Ghiso J. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. *Acta Neuropathol.* 2009; 118:115–130. [PubMed: 19225789]

26. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β -amyloid. *Nat Genet.* 1992; 1:345–347. [PubMed: 1302033]
27. Cai XD, Golde TE, Younkin S. Release of excess amyloid β protein from a mutant amyloid β protein precursor. *Science.* 1993; 259:514–516. [PubMed: 8424174]
28. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the β -amyloid precursor protein in familial Alzheimer's disease increases β -protein production. *Nature.* 1992; 360:672–674. [PubMed: 1465129]
29. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone C, Gobbi M, Colombo L, Bastone A, Beeg M, Manzoni C, Francescucci B, Spagnoli A, Cantù L, Del Favero E, Levy E, Salmona M, Tagliavini F. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. *Science.* 2009; 323:1473–1477. [PubMed: 19286555]
30. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, Golde TE, Younkin S. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (APP717) mutants. *Science.* 1994; 264:1336–1340. [PubMed: 8191290]
31. Wakutani Y, Watanabe K, Adachi Y, Wada-Isoe K, Urakami K, Ninomiya H, Saido TC, Hashimoto T, Iwatsubo T, Nakashima K. Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. *J Neurol Neurosurg Psychiatry.* 2004; 75:1039–1042. [PubMed: 15201367]
32. Levy E, Carman MD, Fernandez Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. *Science.* 1990; 248:1124–1126. [PubMed: 2111584]
33. Bornebroek M, Haan J, Roos N. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D): a review of the variety in phenotypic expression. *Amyloid.* 1999; 6:215–224. [PubMed: 10524288]
34. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S, Abramowski D, Stürchler-Pierrat C, Bürki K, van Duinen SG, Maat-Schieman MLC, Staufenbiel M, Mathews PM, Jucker M. A β is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. *Nat Neurosci.* 2004; 7:954–960. [PubMed: 15311281]
35. Maat-Schieman MLC, Yamaguchi H, Hegeman-Kleinn IM, Welling-Graafland C, Natté R, Roos RAC, van Duinen S. Glial reactions and the clearance of amyloid β protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. *Acta Neuropathol.* 2004; 107:389–398. [PubMed: 15014955]
36. Maat-Schieman M, Yamaguchi H, van Duinen S, Natté R, Roos RA. Age-related plaque morphology and C-terminal heterogeneity of amyloid β in Dutch-type hereditary cerebral hemorrhage with amyloidosis. *Acta Neuropathol.* 2000; 99:409–419. [PubMed: 10787040]
37. Natté R, Maat-Schieman M, Haan J, Bornebroek M, Roos R, van Duinen S. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles. *Ann Neurol.* 2001; 50:765–772. [PubMed: 11761474]
38. Castano EM, Prelli F, Soto C, Beavis R, Matsubara E, Shoji M, Frangione B. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. *J Biol Chem.* 1996; 271:32185–32191. [PubMed: 8943274]
39. Prelli F, Levy E, van Duinen SG, Bots GT, Luyendijk W, Frangione B. Expression of a normal and variant Alzheimer's β -protein gene in amyloid of hereditary cerebral hemorrhage, Dutch type: DNA and protein diagnostic assays. *Biochem Biophys Res Commun.* 1990; 170:301–307. [PubMed: 2196878]
40. Nishitsuji K, Tomiyama T, Ishibashi K, Ito K, Teraoka R, Lambert MP, Klein WL, Mori H. The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. *Am J Pathol.* 2009; 174:957–969. [PubMed: 19164507]
41. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J. Substitution at codon 22 of Alzheimer's A β peptide induce diverse conformational changes and

- apoptotic effects in human cerebral endothelial cells. *J Biol Chem.* 2000; 275:27110–27116. [PubMed: 10821838]
42. Davis JB, van Nostrand WE. Enhanced pathologic properties of Dutch-type mutant amyloid beta-protein. *Proc Natl Acad Sci USA.* 1996; 93:2996–3000. [PubMed: 8610157]
 43. Viana RJ, Nunes AF, Castro RE, Ramalho RM, Meyerson J, Fossati S, Ghiso J, Rostagno A, Rodrigues CM. Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. *Cell Mol Life Sci.* 2009; 66:1094–1104. [PubMed: 19189048]
 44. Solito R, Corti F, Fossati S, Mezhericher E, Donnini S, Ghiso J, Giachetti A, Rostagno A, Ziche M. Dutch and Arctic mutant peptides of beta amyloid(1–40) differentially affect the FGF-2 pathway in brain endothelium. *Exp Cell Res.* 2009; 315:385–395. [PubMed: 19061884]
 45. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R, Imagawa M, Ataka S, Wada Y, Yoshioka E, Nishizaki T, Watanabe Y, Mori H. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. *Ann Neurol.* 2008; 63:377–387. [PubMed: 18300294]
 46. Takuma H, Teraoka R, Mori H, Tomiyama T. Amyloid β E22delta variant induces synapse alteration in mouse hippocampal slices. *Neuroreport.* 2007; 19:615–619. [PubMed: 18382273]
 47. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. *Nat Neurosci.* 2001; 4:887–893. [PubMed: 11528419]
 48. Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O'dahl S, Nemens E, White JA, Sadovnick AD, Ball MJ, Kaye JA, Warren A, McInnis MG, Antonarakis SE, Korenberg JR, Sharma V, Kukull WA, Larson EB, Heston LL, Martin GM, Bird TD, Schellenberg GD. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. *Am J Hum Genet.* 1992; 51:998–1014. [PubMed: 1415269]
 49. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, Hofman A, Van Broeckhoven C. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. *Nat Genet.* 1992; 1:218–221. [PubMed: 1303239]
 50. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow D. Amyloid β -protein fibrillogenesis. Detection of a proto-fibrillar intermediate. *J Biol Chem.* 1997; 272:22364–22372. [PubMed: 9268388]
 51. van Nostrand WE, Melchor JP, Cho HS, Greenberg SM, Rebeck GW. Pathogenic effects of D23N Iowa mutant amyloid β -protein. *J Biol Chem.* 2001; 276:32860–32866. [PubMed: 11441013]
 52. Walsh DM, Hartley DM, Condron MM, Selkoe DJ, Teplow DB. In vitro studies of amyloid β -protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala⁶⁹²→Gly) Alzheimer's disease. *Biochem J.* 2001; 355:869–877. [PubMed: 11311152]
 53. Grabowski TJ, Cho HS, Vonsattel JPG, Rebeck GW, Greenberg SM. A novel APP mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. *Ann Neurol.* 2001; 49:697–705. [PubMed: 11409420]
 54. Zhang-Nunes SX, Maat-Schieman M, van Duinen S, Roos R, Frosch MP, Greenberg SM. The cerebral β -amyloid angiopathies: hereditary and sporadic. *Brain Pathol.* 2006; 16:30–39. [PubMed: 16612980]
 55. Greenberg SM, Shin Y, Grabowski TJ, Cooper GE, Rebeck GW, Iglesias S, Chapon F, Tournier-Lasserre E, Baron JC. Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation. *Neurology.* 2003; 60:1020–1022. [PubMed: 12654973]
 56. Iglesias S, Chapon F, Baron JC. Familial occipital calcifications, hemorrhagic strokes, leukoencephalopathy, dementia, and external carotid dysplasia. *Neurology.* 2000; 55:1661–1667. [PubMed: 11113220]
 57. Shin Y, Cho HS, Rebeck GW, Greenberg BD. Vascular changes in Iowa-type hereditary cerebral amyloid angiopathy. *Ann N Y Acad Sci.* 2002; 977:245–251. [PubMed: 12480757]
 58. Shin Y, Cho HS, Fukumoto H, Shimizu T, Shirasawa T, Greenberg SM, Rebeck GW. Abeta species, including IsoAsp23 Abeta, in Iowa-type familial cerebral amyloid angiopathy. *Acta Neuropathol.* 2003; 105:252–258. [PubMed: 12557012]

59. Tomidokoro Y, Rostagno A, Greenberg SM, Frangione B, Rebeck GW, Ghiso J. Biochemical analysis of A β amyloid deposits in the Iowa variant of Alzheimer's disease. *Neurobiol Aging*. 2004; 25:38.
60. Gabizon R, Telling G, Meiner Z, Halimi M, Kahana I, Prusiner SB. Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. *Nat Med*. 1996; 2:59–64. [PubMed: 8564843]
61. Ando Y, Ando E, Ohlsson PI, Olofsson A, Sandgren O, Suhr O, Terazaki H, Obayashi K, Lundgren E, Ando M, Negi A. Analysis of transthyretin amyloid fibrils from vitreous samples in familial amyloidotic polyneuropathy (Val30Met). *Amyloid*. 1999; 6:119–123. [PubMed: 10439118]
62. Thylén C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modification of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. *EMBO J*. 1993; 12:743–748. [PubMed: 8095018]
63. Dwulet FE, Benson MD. Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). *J Clin Invest*. 1986; 78:880–886. [PubMed: 3760189]
64. Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, Harihara Y, Baba S, Kametani F, Ikeda SI. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. *Biochem Biophys Res Commun*. 2000; 274:702–706. [PubMed: 10924339]
65. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. *Muscle Nerve*. 2003; 28:438–442. [PubMed: 14506715]
66. Tomidokoro Y, Lashley T, Rostagno A, Neubert TA, Bojsen-Moller M, Braendgaard H, Plant G, Holton J, Frangione B, Revesz T, Ghiso J. Familial Danish dementia: co-existence of ADan and A β amyloid subunits in the absence of compact plaques. *J Biol Chem*. 2005; 280:36883–36894. [PubMed: 16091362]
67. Frangione B.; Wisniewski, T.; Tagliavini, F.; Bugiani, O.; Ghiso, J. Alzheimer's disease and Dutch variant: opposing faces of a single coin. In: Corain, B.; Iqbal, K.; Nicolini, B.; Winblad, B.; Wisniewski, HM.; Zatta, P., editors. *Alzheimer's disease: advances in clinical and basic research*. Wiley, Chichester; 1993. p. 387-396.
68. Wisniewski T, Golabek AA, Kida E, Wisniewski KE, Frangione B. Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. *Am J Pathol*. 1995; 147:238–244. [PubMed: 7639323]
69. Davis JB, Cribbs DH, Cotman CW, van Nostrand WE. Pathogenic amyloid beta-protein induces apoptosis in cultured human cerebrovascular smooth muscle. *Amyloid*. 1999; 6:157–164. [PubMed: 10524279]
70. Obici L, Demarchi A, de Rosa G, Bellotti V, Marciano S, Donadei S, Arbustini E, Palladini G, Diegoli M, Genovese E, Ferrari G, Coverlizza S, Merlini G. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. *Ann Neurol*. 2005; 58:639–644. [PubMed: 16178030]
71. Cam, J.; Meyerson, J.; Mezhericher, E.; Frangione, B.; Ghiso, J.; Rostagno, A. Differential apoptotic response of primary human cerebral endothelial cells to oligomeric assemblies of amyloid beta genetic variants. In: Fisher, A.; Hanin, I.; Poewe, W.; Windisch, M., editors. *New trends in Alzheimer and Parkinson disorders*. Medimond International Proceedings; Bologna, Italy: 2007. p. 141-146.
72. Fossati S, Cam J, Meyerson J, Mezhericher E, Romero IA, Couraud PO, Weksler B, Ghiso J, Rostagno A. Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid- β variants in cells composing the cerebral vessel walls. *FASEB J*. 2009 Epub ahead of print.
73. Rossi G, Giaccone G, Maletta R, Morbin M, Capobianco R, Mangieri M, Giovagnoli AR, Bizzi A, Tomaino C, Perri M, Di Natale M, Tagliavini F, Bugiani O, Bruni AC. A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. *Neurology*. 2004; 63:910–912. [PubMed: 15365148]

74. Carter DA, Desmarais E, Bellis M, Campion D, Clerget-Darpoux F, Brice A, Agid Y, Jaillard-Serradt A, Mallet J. More missense in amyloid gene. *Nat Genet.* 1992; 2:255–256. [PubMed: 1303275]
75. Armstrong J, Boada M, Rey MJ, Vidal N, Ferrer I. Familial Alzheimer disease associated with A713T mutation in APP. *Neuroreport.* 2004; 370:241–243.
76. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology.* 1984; 34:939–944. [PubMed: 6610841]
77. Hori Y, Hashimoto T, Wakutani Y, Urakami K, Nakashima K, Condrón MM, Tsubuki S, Saido T, Teplow D, Iwatsubo T. The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate A β fibril formation without increasing protofibril formation. *J Biol Chem.* 2007; 282:4916–4923. [PubMed: 17170111]
78. Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houlden H, Rossor MN, Collinge J. Early onset familial Alzheimer's disease. Mutation frequency in 31 families. *Neurology.* 2003; 60:235–239. [PubMed: 12552037]
79. Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. *Ann Med.* 2008; 40:562–583. [PubMed: 18608129]
80. Qahwash I, He W, Tomasselli A, Kletzien RF, Yan R. Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1. *J Biol Chem.* 2004; 279:39010–39016. [PubMed: 15234966]
81. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley YHF, Guenette SY, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD, Tanzi RE. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science.* 1995; 269:973–977. [PubMed: 7638622]
82. Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning. *Neurology.* 2000; 54:2045–2054. [PubMed: 10851361]
83. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, Sherrington R, Hutton M, Hardy J, St George-Hyslop PH, Hofman A, Van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. *Hum Mol Genet.* 1998; 7:43–51. [PubMed: 9384602]
84. Finckh U, Müller-Thomsen T, Mann U, Eggers C, Marksteiner J, Meins W, Binetti G, Alberici A, Hock C, Nitsch RM, Gal A. High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes. *Am J Hum Genet.* 2000; 66:110–117. [PubMed: 10631141]
85. Lleo A, Blesa R, Gendre J, Castellví M, Pastor P, Queralt R, Oliva R. A novel presenilin 2 gene mutation (D439A) in a patient with early-onset Alzheimer's disease. *Neurology.* 2001; 57:1926–1928. [PubMed: 11723295]
86. Ezquerra M, Lleo A, Castellví M, Queralt R, Santacruz P, Pastor P, Molinuevo JL, Blesa R, Oliva R. A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. *Arch Neurol.* 2003; 60:1149–1151. [PubMed: 12925374]
87. Marcon G, Di Fede G, Giaccone G, Rossi G, Giovagnoli AR, Maccagnano E, Tagliavini F. A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype. *J Alzheimers Dis.* 2009; 16:509–511. [PubMed: 19276543]
88. Lippa CF, Swearer JM, Kane KJ, Nochlin D, Bird TD, Ghetti B, Nee LE, St George-Hyslop P, Pollen DA, Drachman DA. Familial Alzheimer's disease: site of mutation influences clinical phenotyp. *Ann Neurol.* 2000; 48:376–379. [PubMed: 10976645]
89. Finckh U, Alberici A, Antoniazzi M, Benussi L, Fedi V, Giannini C, Gal A, Nitsch RM, Binetti G. Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. *Neurology.* 2000; 54:2006–2008. [PubMed: 10822446]
90. Bird TD, Levy-Lahad E, Poorkaj P, Sharma V, Nemens E, Lahad A, Lampe TH, Schellenberg GD. Wide range in age of onset for chromosome 1—related familial Alzheimer's disease. *Ann Neurol.* 1996; 40:932–936. [PubMed: 9007102]

91. Steiner H, Revesz T, Neumann M, Romig H, Grim MG, Pesold B, Kretzschmar HA, Hardy J, Holton J, Baumeister R, Houlden H, Haass C. A pathogenic presenilin-1 deletion causes aberrant Abeta 42 production in the absence of congophilic amyloid plaques. *J Biol Chem.* 2001; 276:7233–7239. [PubMed: 11084029]
92. Gudmundsson G, Hallgrimsson J, Jonasson T, Bjarnason O. Hereditary cerebral hemorrhage with amyloidosis. *Brain.* 1972; 95:387–404. [PubMed: 4655034]
93. Levy E, Lopez-Otin C, Ghiso J, Geltner D, Frangione B. Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. *J Exp Med.* 1989; 169:1771–1778. [PubMed: 2541223]
94. Ghiso J, Jenson O, Frangione B. Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C). *Proc Natl Acad Sci USA.* 1986; 83:2974–2978. [PubMed: 3517880]
95. Ghiso J, Pons-Estel B, Frangione B. Hereditary cerebral amyloid angiopathy: the amyloid contain a protein which is a variant of cystatin C, an inhibitor of lysosomal cysteine proteases. *Biochem Biophys Res Commun.* 1986; 136:548–554. [PubMed: 3707586]
96. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. *Brain Pathol.* 2006; 16:60–70. [PubMed: 16612983]
97. Janowski R, Kozak M, Jankowska E, Grzonka Z, Grubb A, Abrahamson M, Jaskolski M. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. *Nat Struct Biol.* 2001; 8:316–320. [PubMed: 11276250]
98. Janowski R, Kozak M, Abrahamson M, Grubb A, Jaskolski M. 3D Domain-swapped human cystatin C with amyloid like intermolecular -sheets. *Struct Funct Bioinform.* 2005; 61:570–578.
99. Janowski R, Abrahamson M, Grubb A, Jaskolski M. Domain swapping in N-truncated cystatin C. *J Mol Biol.* 2004; 341:151–160. [PubMed: 15312769]
100. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton J. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. *J Neuropathol Exp Neurol.* 2003; 62:885–898. [PubMed: 14533778]
101. Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. *Amyloid.* 1998; 5:55–66. [PubMed: 9547007]
102. Haltia M, Ghiso J, Prelli F, Gallo G, Kiuru S, Somer H, Palo J, Frangione B. Amyloid in familial amyloidosis, Finnish type, is antigenically and structurally related to gelsolin. *Am J Pathol.* 1990; 136:223–228.
103. Haltia M, Prelli F, Ghiso J, Kiuru S, Somer H, Palo J, Frangione B. Amyloid protein in familial amyloidosis (Finnish type) is homologous to gelsollin, an actin-binding protein. *Biochem Biophys Res Commun.* 1990; 176:927–932. [PubMed: 2157434]
104. Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B. Mutation in gelsolin gene in Finnish hereditary amyloidosis. *J Exp Med.* 1990; 172:1865–1867. [PubMed: 2175344]
105. Ghiso J, Haltia M, Prelli F, Novello J, Frangione B. Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type. *Biochem J.* 1990; 272:827–830. [PubMed: 2176481]
106. Garzuly F, Vidal R, Wisniewski T, Brittig F, Budka H. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). *Neurology.* 1996; 47:1562–1567. [PubMed: 8960746]
107. Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, Frangione B, Wisniewski T. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). *Am J Pathol.* 1996; 148:351–354. [PubMed: 8579096]
108. Petersen RB, Goren H, Cohen M, Richardson SL, Tresser N, Lynn A, Gali M, Estes M, Gambetti P. Transthyretin amyloidosis: a new mutation associated with dementia. *Ann Neurol.* 1997; 41:307–313. [PubMed: 9066351]
109. Frangione B, Vidal R, Rostagno A, Ghiso J. Familial cerebral amyloid angiopathies and dementia. *Alzheimer Dis Assoc Disord.* 2000; 14:S25–S30. [PubMed: 10850727]
110. Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M. Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. *Pathol Int.* 2001; 51:476–480. [PubMed: 11422811]

111. Schröder R, Deckert M, Linke RP. Novel isolated cerebral ALlambda amyloid angiopathy with widespread subcortical distribution and leukoencephalopathy due to atypical monoclonal plasma cell proliferation, and terminal systemic gammopathy. *J Neuropathol Exp Neurol*. 2009; 68:286–299. [PubMed: 19225408]
112. Vidal R, Ghiso J, Gallo G, Cohen M, Gambetti PL, Frangione B. Amyloidoma of the CNS. II. Immunohistochemical and biochemical study. *Neurology*. 1992; 42:2024–2028. [PubMed: 1383872]
113. Fischer B, Palkovic S, Rickert C, Weckesser M, Wassmann H. Cerebral AL lambda-amyloidoma: clinical and pathomorphological characteristics. Review of the literature and of a patient. *Amyloid*. 2007; 14:11–19. [PubMed: 17453621]
114. Simoons WA, Van den Hauwe L, Van Hedent E, Warson F, Demaeseneer R, Williams D, De Schepper AMA. Amyloidoma of the skull base. *Am J Neuroradiol*. 2000; 21:1559–1562. [PubMed: 11003297]
115. Vorster SJ, Lee JH, Ruggieri P. Amyloidoma of the Gasserian ganglion. *Am J Neuroradiol*. 1998; 19:1853–1855. [PubMed: 9874536]
116. McKechnie S, Yang F, Harper CG, McGee-Collett M, Henderson CJA, Liepnieks JJ, Yazaki M, Benson MD, McLeod JG. Amyloidoma of a spinal root. *Neurology*. 2003; 61:834–836. [PubMed: 14504333]
117. Mulleman D, Flipo RM, Assaker R. Primary amyloidoma of the axis and acute spinal cord compression: a case report. *Eur Spine J*. 2004; 13:244–248. [PubMed: 15024637]
118. Consales A, Roncaroli F, Salvi F, Poppi M. Amyloidoma of the brachial plexus. *Surg Neurol*. 2003; 59:418–423. [PubMed: 12765823]
119. Rodriguez FJ, Gamez JD, Vrana JA, Theis JD, Giannini C, Scheithauer BW, Parisi JE, Lucchinetti CF, Pendlebury WW, Bergen HRr, Dogan A. Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. *Lab Invest*. 2008; 88:1024–1037. [PubMed: 18711355]
120. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, Prusiner SB. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. *Proc Natl Acad Sci USA*. 1993; 90:10962–10966. [PubMed: 7902575]
121. Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M, Perini F, Kitamoto T, Tateishi J, Seiler C, Frangione B, Bugiani O, Giaccone G, Prelli F, Goedert M, Dlouhy SR, Tagliavini F. Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. *Proc Natl Acad Sci USA*. 1996; 93:744–748. [PubMed: 8570627]
122. Paulick MG, Bertozzi CR. The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. *Biochemistry*. 2008; 47:6991–7000. [PubMed: 18557633]
123. Rostagno A, Tomidokoro Y, Lashley T, Ng D, Plant G, Holton J, Frangione B, Revesz T, Ghiso J. Chromosome 13 dementias. *Cell Mol Life Sci*. 2005; 62:1814–1825. [PubMed: 15968464]
124. Ghiso J, Vidal R, Rostagno A, Miravalle L, Holton J, Revesz T, Plant G, Frangione B. Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13. In: Growdon J, Wurtman R, Corkin S, Nitsch R, editors. *Molecular basis of dementia*. Vol. 927. New York Academy of Sciences; New York: 2000. p. 84-92.
125. Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L. The familial dementia BRI2 gene binds the Alzheimer's gene amyloid-beta precursor protein and inhibits amyloid-beta production. *J Biol Chem*. 2005; 280:28912–28916. [PubMed: 15983050]
126. Matsuda S, Giliberto L, Matsuda T, McGowan E, D'Adamio L. BRI2 inhibits amyloid beta peptide precursor protein processing by interfering with the docking of secretases to the substrate. *J Neurosci*. 2008; 28:8668–8676. [PubMed: 18753367]
127. Fotinopoulou A, Tsachaki M, Vlavaki M, Pouloupoulos A, Rostagno A, Frangione B, Ghiso J, Efthimiopoulos S. BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. *J Biol Chem*. 2005; 280:30768–30772. [PubMed: 16027166]

128. Kim J, Miller VM, Levites Y, West KJ, Zwizinski CW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K, Rangachari V, Zou F, Younkin S, Graff-Radford N, Dickson D, Rosenberry T, Golde TE. BRI2 (Itm2b) inhibits A β deposition in vivo. *J Neurosci*. 2008; 28:6030–6036. [PubMed: 18524908]
129. Worster-Drought C, Hill T, McMenemey W. Familial presenile dementia with spastic paralysis. *J Neurol Psychopathol*. 1933; 14:27–34. [PubMed: 21610757]
130. Ghiso J, Holton J, Miravalle L, Calero M, Lashley T, Vidal R, Houlden H, Wood N, Neubert TA, Rostagno A, Plant G, Revesz T, Frangione B. Systemic amyloid deposits in Familial British Dementia. *J Biol Chem*. 2001; 276:43909–43914. [PubMed: 11557758]
131. Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J. A stop-codon mutation in the *BRI* gene associated with familial British dementia. *Nature*. 1999; 399:776–781. [PubMed: 10391242]
132. Vidal R, Ghiso J, Revesz T, Rostagno A, Kim E, Holton J, Bek T, Bojsen-Moller M, Braendgaard H, Plant G, Frangione B. A decamer duplication in the 3' region of the *BRI* gene originates a new amyloid peptide that is associated with dementia in a Danish kindred. *Proc Natl Acad Sci USA*. 2000; 97:4920–4925. [PubMed: 10781099]
133. Ghiso J, Rostagno A, Tomidokoro Y, Lashley T, Bojsen-Moller M, Braendgaard H, Plant G, Holton J, Lal R, Revesz T, Frangione B. Genetic alterations of the BRI2 gene: familial British and Danish dementias. *Brain Pathol*. 2006; 16:71–79. [PubMed: 16612984]
134. Holton J, Ghiso J, Lashley T, Rostagno A, Guerin C, Gibb G, Houlden H, Ayling H, Martinian L, Anderton B, Wood N, Vidal R, Plant G, Frangione B, Revesz T. Regional distribution of fibrillar and non-fibrillar ABri deposition and its association with neurofibrillary degeneration in Familial British Dementia. *Am J Pathol*. 2001; 158:515–526. [PubMed: 11159188]
135. Holton J, Lashley T, Ghiso J, Braendgaard H, Vidal R, Guerin C, Gibb G, Hanger DP, Rostagno A, Anderton B, Strand C, Ayling H, Plant G, Frangione B, Bojsen-Moller M, Revesz T. Familial Danish Dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. *J Neuropathol Exp Neurol*. 2002; 61:254–267. [PubMed: 11895040]
136. Saido T, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct β -amyloid peptide species, A β N3(pE), in senile plaques. *Neuron*. 1995; 14:457–466. [PubMed: 7857653]
137. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK. Heterogeneity of water-soluble amyloid b-peptide in Alzheimer's disease and Down's syndrome brains. *FEBS Lett*. 1997; 409:411–416. [PubMed: 9224700]
138. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G. Pyroglutamate-modified amyloid β -peptides—A β N3(pE)—strongly affect cultured neuron and astrocyte survival. *J Neurochem*. 2002; 82:1480–1489. [PubMed: 12354296]
139. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Böhm G, Demuth HU. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). *Biochemistry*. 2006; 45:12394–12399.
140. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. *Amyloid*. 2005; 12:1–4. [PubMed: 16076605]
141. Kirschner DA, Abraham C, Selkoe DJ. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross- β conformation. *Proc Natl Acad Sci USA*. 1986; 83:503–507. [PubMed: 3455785]
142. Westermark P, Benson MD, Buxbaum J, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. A primer of amyloid nomenclature. *Amyloid*. 2007; 14:179–183. [PubMed: 17701465]
143. Mandelkow E, Song YH, Schweers O, Marx A, Mandelkow EM. On the structure of microtubules, tau, and paired helical filaments. *Neurobiol Aging*. 1995; 16:347–354. [PubMed: 7566344]

144. Goedert M, Klug A, Crowther RA. Tau protein, the paired helical filament and Alzheimer's disease. *J Alzheimers Dis.* 2006; 9:195–207. [PubMed: 16914859]
145. Delacourte A, Buee L. Tau pathology: a marker of neurodegenerative disorders. *Curr Opin Neurol.* 2000; 13:371–376. [PubMed: 10970052]
146. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Rev.* 2000; 33:95–130. [PubMed: 10967355]
147. Caughey B, Lansbury PTJ. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. *Annu Rev Neurosci.* 2003; 26:267–298. [PubMed: 12704221]
148. Walsh DM, Selkoe DJ. A beta oligomers—a decade of discovery. *J Neurochem.* 2007; 101:1172–1184. [PubMed: 17286590]
149. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of A beta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann Neurol.* 1999; 46:860–866. [PubMed: 10589538]
150. Lue LF, Kuo YM, Roher A, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel R, Rogers J. Soluble amyloid beta concentration is a predictor of synaptic change in Alzheimer's disease. *Am J Pathol.* 1999; 155:853–862. [PubMed: 10487842]
151. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch C, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proc Natl Acad Sci USA.* 2003; 100:10417–10422. [PubMed: 12925731]
152. Kaye R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science.* 2003; 300:486–489. [PubMed: 12702875]
153. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. *Nat Rev Mol Cell Biol.* 2007; 8:101–112. [PubMed: 17245412]
154. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. *J Mol Biol.* 2002; 322:1089–1102. [PubMed: 12367530]
155. Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from α -synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. *Biochemistry.* 2000; 39:2552–2563. [PubMed: 10704204]
156. Conway KA, Harper JD, Lansbury PTJ. Accelerated in vitro fibril formation by a mutant α -synuclein linked to early-onset Parkinson disease. *Nat Med.* 1998; 4:1318–1320. [PubMed: 9809558]
157. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. *Proc Natl Acad Sci USA.* 2000; 97:571–576. [PubMed: 10639120]
158. Marchut AJ, Hall CK. Spontaneous formation of annular structures observed in molecular dynamics simulations of polyglutamine peptides. *Comput Biol Chem.* 2006; 30:215–218. [PubMed: 16678490]
159. Quist A, Doudevski I, Lin H, Azimova D, Ng D, Frangione B, Kagan B, Ghiso J, Lal R. Amyloids form membrane pores: a common structural link for protein-misfolding disease. *Proc Natl Acad Sci USA.* 2005; 102:10427–10432. [PubMed: 16020533]

Fig. 1.

Immunohistochemical analysis of amyloid deposits in cerebral amyloidosis. **a** $A\beta$ -positive plaques (*arrow*) and **b** cerebral amyloid angiopathy (*double arrow*) in a case of Alzheimer's disease. **c** Neurofibrillary tangles (*arrow*), neuropil threads and plaque-associated abnormal neurites (*double arrow*) demonstrated with tau immunohistochemistry in Alzheimer's disease. **d** $A\beta$ deposition in blood vessels (*double arrow*) and diffuse parenchymal plaques (*arrow*) in the cerebral cortex in HCHWA-D. **e** Deposition of $A\beta$ -peptide in characteristic cotton wool plaques (*arrow*) together with severe CAA (*double arrow*) is a feature of familial Alzheimer's disease with $\Delta I83/\Delta M84$ *PS1* mutation. **f** Accumulation of mutated

cystatin C in leptomeningeal blood vessels in a case of HCHWA-Icelandic type. **g** AGel deposition in skin blood vessels in familial amyloidosis of the Finnish type. **h** ATTR deposition in leptomeningeal blood vessels in the Hungarian form of meningoarteriosclerosis. **i** Widespread ABri deposition in large parenchymal plaques (*arrow*) and ABri CAA (*double arrow*) in familial British dementia. **j** Severe CAA (*double arrow*) and diffuse plaques (*arrow*) due to ADan deposition in familial Danish dementia

Fig. 2. Pathogenic mutations in exons 16 and 17 of APP. The diagram summarizes the location, nucleotide change, disease onset, and frequency of each of the known pathogenic mutations. Variations in Aβ40 and Aβ42 concentrations secreted by transfected cells in culture are also indicated

Table 1

Human amyloid subunits linked to disease

Biological function of the precursor protein	Protein precursor of the amyloid subunit	Chromosome	Amyloid subunit	Systemic (S) or organ-restricted (R)	Central nervous system	Sporadic (S) or hereditary (H)
Immune system associated proteins	Light chain λ	22	ALA	S, R	Yes	S
	Light chain κ	2	AL κ	S, R	Yes	S
	Heavy chain γ	14	AH γ	S, R	No	S
	Heavy chain μ	14	AH μ	S, R	No	S
	Heavy chain α	14	AH α	S, R	No	S
Apolipoproteins	β 2-Microglobulin	15	A β 2M	S	No	S
	apoSAA	11	AA	S	No	S
	apoA-I	11	AApoA-I	S	No	H
	apoA-II	1	AApoA-II	S	No	H
	apoA-IV	11	AApoA-IV	S	No	H
Transport proteins	Transthyretin	18	ATTR	S	Yes	S, H
Regulatory proteins	Lactoferrin	3	ALac	R	No	H
	Gelsolin	9	AGel	S	Yes	H
Coagulation factors	Semenogelin I	20	ASem	R	No	H
	Fibrinogen, α chain	4	AFib	S	No	H
	Calcitonin	11	ACal	R	No	H
Hormones	Prolactin	6	APro	R	No	H
	Atrial natriuretic factor	1	AANF	R	No	H
	Amylin	12	AIAPP	R	No	H
Enzymes	Insulin	11	AIns	R	No	H
	Lysozyme	12	ALys	S	No	H
Enzymatic inhibitors	Cystatin C	20	ACys	S	Yes	H
Cell receptor	Oncostatin M receptor	5	AOMR	R	No	S, H
Cell adhesion proteins	Keratopithelin	5	AKep	R	No	H
Cytoskeletal proteins	Tau	17	ATau	R	Yes	S, H
	Keratin	12,17	AKer	R	No	H
Infectious agents	Prion protein	20	APrP ^{Sc}	R	Yes	S, H
Proteins of unknown biological function	Lactadherin	15	AMed	R	No	Unknown

Biological function of the precursor protein	Protein precursor of the amyloid subunit	Chromosome	Amyloid subunit	Systemic (S) or organ-restricted (R)	Central nervous system	Sporadic (S) or hereditary (H)
	ODAM	4	AOaap	R	No	H
	A β precursor protein	21	A β	R	Yes	S, H
	ABri precursor protein	13	ABri	S	Yes	H
	ADan precursor protein	13	ADan	S	Yes	H